Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has closed a non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, securing approximately CAD$5 million in notional subscription. The financing, structured as an 18-month sharing arrangement tied to the volume-weighted average trading price of the company's shares, will provide capital to advance Onco-Innovations' oncology pipeline, particularly the ONC010 program and its SynoGraph platform.
The placement involved the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, with each unit comprising one common share and one warrant exercisable at CAD$0.77 for three years. Monthly settlement amounts will vary based on market performance, allowing the company to access funds gradually. Onco-Innovations intends to use the net proceeds to support manufacturing and preclinical activities for ONC010, continue development of the SynoGraph platform, and provide working capital for general corporate purposes.
This financing is significant for Onco-Innovations as it provides a financial runway to progress its lead programs toward key milestones. The ONC010 program targets solid tumors using patented technology exclusively licensed to the company. Meanwhile, the SynoGraph platform represents a novel approach to cancer treatment, though details remain under wraps. The capital injection comes at a critical time when many early-stage biotech firms struggle to secure funding amid volatile markets.
The involvement of institutional investors like Sorbie Bornholm LP and Sorbie Investments LLP signals confidence in Onco-Innovations' strategy and technology. The structured payout mechanism allows the company to manage dilution while accessing needed capital. For investors, the warrants provide upside potential if the stock performs well, aligning incentives with the company's success.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment. The company's mission focuses on pioneering research and innovative solutions for the prevention and treatment of cancer. With this funding, Onco-Innovations can advance its preclinical work and move closer to clinical trials, potentially offering new treatment options for patients with solid tumors.
The full press release detailing the private placement is available at https://ibn.fm/1Hrlg. For the latest news and updates regarding ONNVF, visit the company's newsroom at https://ibn.fm/ONNVF.
